← Back to Discover
SymBiosis Capital Partners, LLC
Period ended Mar 31, 2026 · Latest filing May 12, 2026
These quarterly holdings are delayed and may not include all assets or short positions.
Values are from the reporting date, not current prices or purchase costs.
The same security may appear in multiple rows.
Source: SEC
Reported portfolio value
Quarter-end reported holdings; not current value or investment performance.
View reported values
- Mar 31, 2026: $52,769,920
More quarters will appear as history becomes available.
Top holdings
Top 10 at Mar 31, 2026. Matching entries are combined; security classes and options remain separate. Shares exclude principal amounts; option shares reflect the reported underlying amount.
View top holdings values
- Evommune, Inc. · COM SHS · 30054Y107 · shares: $29,445,086
- Inventiva S.A. · ADS · 46124U107 · shares: $13,064,700
- Wave Life Sciences Ltd. · SHS · Y95308105 · shares: $5,437,500
- Rani Therapeutics Holdings, Inc. · COM CL A · 753018100 · shares: $2,694,941
- Clene Nanomedicine Inc. · COM NEW · 185634201 · shares: $2,125,293
- Surrozen, Inc. · *W EXP 08/01/203 · 86889P117 · shares: $2,400
Reported holdings
6 reported entries| Issuer | Class | CUSIP | Type | Shares / principal | Reported value (USD) |
|---|---|---|---|---|---|
| Evommune, Inc. | COM SHS | 30054Y107 | — | 1,280,778 shares | $29,445,086 |
| Inventiva S.A. | ADS | 46124U107 | — | 2,354,000 shares | $13,064,700 |
| Wave Life Sciences Ltd. | SHS | Y95308105 | — | 750,000 shares | $5,437,500 |
| Rani Therapeutics Holdings, Inc. | COM CL A | 753018100 | — | 3,667,585 shares | $2,694,941 |
| Clene Nanomedicine Inc. | COM NEW | 185634201 | — | 431,094 shares | $2,125,293 |
| Surrozen, Inc. | *W EXP 08/01/203 | 86889P117 | — | 150,000 shares | $2,400 |